The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Online Program Home
Abstract Details
|
Activity Number:
|
473
|
|
Type:
|
Contributed
|
|
Date/Time:
|
Wednesday, August 1, 2012 : 8:30 AM to 10:20 AM
|
|
Sponsor:
|
Biopharmaceutical Section
|
| Abstract - #305938 |
|
Title:
|
Estimation of Correlation Between Overall Survival and Surrogate Endpoints
|
|
Author(s):
|
Fang Fang and Liping Huang*+ and Minghua Shan and Xiaosha Zhang
|
|
Companies:
|
Bayer Healthcare Pharmaceuticals and Bayer Healthcare Pharmaceuticals and Bayer Healthcare Pharmaceuticals and Astellas Pharma U.S., Inc.
|
|
Address:
|
340 Changebridge Road, Montville, NJ, ,
|
|
Keywords:
|
oncology ;
overall survival ;
progression free survival ;
time to progression ;
correlation
|
|
Abstract:
|
Overall survival (OS) is the gold standard for measuring clinical benefit in oncology trials. Surrogate measures of survival such as time to progression (TTP) and/or progression free survival (PFS) are clinically relevant endpoints and may be acceptable for drug approval. The correlation between TTP/PFS and OS has investigated by literature-based analysis of randomized trial in different cancer types, including colorectal, colon, breast and non-small cell lung cancer. The statistical models which describe the dependence structure between OS and TTP/PFS are almost non-existing. Observations on OS and TTP/PFS can be censored. We use both parametric approach and bootstrap method to perform the simulation to investigate the correlation between OS and TTP/PFS in the presence of censoring.
|
The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.
Back to the full JSM 2012 program
|
2012 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.